Loading...

AVAX Technologies, Inc.

AVXT•PNK
HealthcareBiotechnology
$0.00
$0.00(0.00%)

AVAX Technologies, Inc. (AVXT) Stock Overview

Explore AVAX Technologies, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for AVXTStats details for AVXT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for AVXTAnalyst Recommendations details for AVXT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

Employees

9

Headquarters

2000 Hamilton Street, Philadelphia, PA

Founded

1997

Frequently Asked Questions